New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma

Although sarcomas account for a small portion of solid malignancies, currently, there are few treatment options for sarcomas, particularly for advanced disease. The mammalian target of rapamycin (mTOR), a serine-threonine protein kinase in the phosphatidylinositol 3-kinase/serine/threonine protein k...

Descripción completa

Detalles Bibliográficos
Autor principal: Agulnik, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412949/
https://www.ncbi.nlm.nih.gov/pubmed/21837674
http://dx.doi.org/10.1002/cncr.26361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412949/
https://www.ncbi.nlm.nih.gov/pubmed/21837674
http://dx.doi.org/10.1002/cncr.26361

Ejemplares similares